Novartis Announced The Pivotal Phase Iii Psmafore Study With Pluvicto (Inn: Lutetium (177Lu) Vipivotide Tetraxetan), A Prostate-Specific Membrane Antigen (Psma)-Targeted Radioligand Therapy, Met Its Primary Endpoint.Pluvicto Demonstrated A Statistically Significant And Clinically Meaningful Improvement In Radiographic Progression-Free Survival (Rpfs) In Patients With Psma
